Cite

HARVARD Citation

    Smit, J. et al. (2022). Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease. Movement disorders. 37 (10), pp. 2045-2056. [Online]. 
  
Back to record